CD4 and neoplasm: Broader characterization of immune populations, including CD8 + T cells, CD4 + T cells, Tregs, and myeloid cells, alongside cytokine profiling, will help identify pathways that influence treatment efficacy and further validate FolTAC-dual’s ability to overcome resistance across diverse tumor contexts.